NetworkNewsBreaks – Acura Pharmaceuticals (ACUR) Inks License Agreement with MainPointe Pharmaceuticals for Nexafed® Products

Acura Pharmaceuticals (OTCQB: ACUR) shares are up 5% on news that the company has entered into a License Agreement with MainPointe Pharmaceuticals, LLC in which MainPointe will exclusively market NEXAFED and NEXAFED Sinus in the U.S. and Canada. The NEXAFED brand products, which contain pseudoephedrine, utilize Acura’s IMPEDE® Technology, which disrupts the extraction and conversion of pseudoephedrine into the illicit drug methamphetamine. MainPointe will assume all manufacturing and commercialization activities from Acura. Per the agreement, MainPointe is required to make an upfront cash payment of $2.5 million to Acura, as well as royalty payments of 7.5% based on commercial sales by MainPointe. “With additional products in distribution and new customer contacts, MainPointe is well positioned to expand on the US pharmacy distribution achieved by Acura over the past several years,” Acura president and CEO Bob Jones stated in the news release.

To view the full press release, visit: http://nnw.fm/5cIZ0

About Acura Pharmaceuticals

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX™, AVERSION® and IMPEDE® Technologies. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted.  IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine. OXAYDO® (oxycodone HCl immediate-release tablets) which incorporates the AVERSION Technology, is FDA approved and marketed in the U.S. by the company’s partner Egalet Corporation. NEXAFED® and NEXAFED® Sinus, which are pseudoephedrine containing products, utilize the IMPEDE Technology. For more information, visit www.acurapharm.com.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s